Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567229 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00567229: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00567229 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00567229, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may be an effective treatment for multiple myeloma. PURPOSE: This phase II trial is studying the side effects of giving lenalidomide together with rituximab and to see how well it works in treating patients with recurrent or refractory multiple myeloma.
Interventions
- GENETIC microarray analysis
- OTHER laboratory biomarker analysis
- BIOLOGICAL rituximab
- DRUG lenalidomide
- OTHER flow cytometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00567229
The ClinicalTrials.gov registry entry for NCT00567229 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00567229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00567229 about?
NCT00567229 is a clinical study titled "Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma". RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry c...
What is the current status of trial NCT00567229?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2007-11. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00567229?
The interventions under investigation include: microarray analysis (GENETIC), laboratory biomarker analysis (OTHER), rituximab (BIOLOGICAL), lenalidomide (DRUG), flow cytometry (OTHER).
Who is sponsoring clinical trial NCT00567229?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.